- Home
- ARI vs JANX Comparison
ARI vs JANX Comparison
Compare ARI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARI
- JANX
- Stock Information
- Founded
- ARI 2009
- JANX 2017
- Country
- ARI United States
- JANX United States
- Employees
- ARI N/A
- JANX N/A
- Industry
- ARI Real Estate Investment Trusts
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- ARI Real Estate
- JANX Health Care
- Exchange
- ARI Nasdaq
- JANX Nasdaq
- Market Cap
- ARI 1.1B
- JANX 1.4B
- IPO Year
- ARI 2009
- JANX 2021
- Fundamental
- Price
- ARI $9.78
- JANX $23.57
- Analyst Decision
- ARI Hold
- JANX Strong Buy
- Analyst Count
- ARI 5
- JANX 7
- Target Price
- ARI $9.83
- JANX $94.29
- AVG Volume (30 Days)
- ARI 1.5M
- JANX 665.3K
- Earning Date
- ARI 08-05-2025
- JANX 08-06-2025
- Dividend Yield
- ARI 10.19%
- JANX N/A
- EPS Growth
- ARI N/A
- JANX N/A
- EPS
- ARI N/A
- JANX N/A
- Revenue
- ARI $276,844,000.00
- JANX $9,336,000.00
- Revenue This Year
- ARI $32.11
- JANX N/A
- Revenue Next Year
- ARI $19.41
- JANX $1,470.82
- P/E Ratio
- ARI N/A
- JANX N/A
- Revenue Growth
- ARI 104.64
- JANX 28.12
- 52 Week Low
- ARI $7.70
- JANX $22.48
- 52 Week High
- ARI $11.20
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- ARI 50.04
- JANX 44.57
- Support Level
- ARI $9.53
- JANX $22.74
- Resistance Level
- ARI $9.91
- JANX $24.73
- Average True Range (ATR)
- ARI 0.15
- JANX 1.23
- MACD
- ARI -0.03
- JANX 0.06
- Stochastic Oscillator
- ARI 46.30
- JANX 32.09
About ARI Apollo Commercial Real Estate Finance Inc
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.